Kezar Life Sciences (KZR) Corporate Presentation summary

Strategic focus and pipeline highlights

• Advancing zetomipzomib, a first-in-class selective immunoproteasome inhibitor, for immune-mediated diseases with a differentiated, non-immunosuppressive approach.

• Positive Phase 2 results in autoimmune hepatitis (AIH) from the PORTOLA study, with plans for registrational development.

• Promising activity also observed in lupus nephritis (LN) and systemic lupus erythematosus (SLE) with favorable safety profile.

• Experienced research and drug development team driving innovation.

Zetomipzomib mechanism and clinical rationale

• Selective immunoproteasome inhibition modulates both innate and adaptive immunity, reducing inflammation without immunosuppression.

• Demonstrated reduction in inflammatory cytokines, increased regulatory T cell function, and decreased autoantibody production.

• Over 200 patients treated, with broad mechanism of action and clinical activity supported by biomarker data.

PORTOLA Phase 2 study in autoimmune hepatitis (AIH)

• Randomized, placebo-controlled trial in relapsed or insufficiently responding AIH patients (n=24), most on steroid-based therapy.

• 36% of zetomipzomib-treated patients on steroids achieved steroid-sparing complete biochemical remission (CR) by week 24 vs. 0% for placebo.

• In the intent-to-treat population, 31.3% achieved CR with zetomipzomib vs. 12.5% with placebo.

• Responses were durable, with no disease flares in CR patients and histologic improvements observed.